698 related articles for article (PubMed ID: 22252816)
1. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
Qureshi ZA; Paterson DL; Potoski BA; Kilayko MC; Sandovsky G; Sordillo E; Polsky B; Adams-Haduch JM; Doi Y
Antimicrob Agents Chemother; 2012 Apr; 56(4):2108-13. PubMed ID: 22252816
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.
Lee GC; Burgess DS
Ann Clin Microbiol Antimicrob; 2012 Dec; 11():32. PubMed ID: 23234297
[TBL] [Abstract][Full Text] [Related]
3. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.
Mouloudi E; Protonotariou E; Zagorianou A; Iosifidis E; Karapanagiotou A; Giasnetsova T; Tsioka A; Roilides E; Sofianou D; Gritsi-Gerogianni N
Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1250-6. PubMed ID: 20973725
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.
Medeiros GS; Rigatto MH; Falci DR; Zavascki AP
Int J Antimicrob Agents; 2019 Feb; 53(2):152-157. PubMed ID: 30722960
[TBL] [Abstract][Full Text] [Related]
5. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
6. Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
Jacobs DM; Safir MC; Huang D; Minhaj F; Parker A; Rao GG
Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):76. PubMed ID: 29178957
[TBL] [Abstract][Full Text] [Related]
7. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.
Zarkotou O; Pournaras S; Tselioti P; Dragoumanos V; Pitiriga V; Ranellou K; Prekates A; Themeli-Digalaki K; Tsakris A
Clin Microbiol Infect; 2011 Dec; 17(12):1798-803. PubMed ID: 21595793
[TBL] [Abstract][Full Text] [Related]
8. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
9. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae.
Falcone M; Bassetti M; Tiseo G; Giordano C; Nencini E; Russo A; Graziano E; Tagliaferri E; Leonildi A; Barnini S; Farcomeni A; Menichetti F
Crit Care; 2020 Jan; 24(1):29. PubMed ID: 32000834
[TBL] [Abstract][Full Text] [Related]
10. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.
Tumbarello M; Viale P; Viscoli C; Trecarichi EM; Tumietto F; Marchese A; Spanu T; Ambretti S; Ginocchio F; Cristini F; Losito AR; Tedeschi S; Cauda R; Bassetti M
Clin Infect Dis; 2012 Oct; 55(7):943-50. PubMed ID: 22752516
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
[No Abstract] [Full Text] [Related]
12. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients.
Freire MP; Pierrotti LC; Filho HH; Ibrahim KY; Magri AS; Bonazzi PR; Hajar L; Diz MP; Pereira J; Hoff PM; Abdala E
Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):277-86. PubMed ID: 25169967
[TBL] [Abstract][Full Text] [Related]
13. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.
Shields RK; Nguyen MH; Potoski BA; Press EG; Chen L; Kreiswirth BN; Clarke LG; Eschenauer GA; Clancy CJ
Antimicrob Agents Chemother; 2015 Mar; 59(3):1797-801. PubMed ID: 25534733
[TBL] [Abstract][Full Text] [Related]
14. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.
Tumbarello M; Trecarichi EM; De Rosa FG; Giannella M; Giacobbe DR; Bassetti M; Losito AR; Bartoletti M; Del Bono V; Corcione S; Maiuro G; Tedeschi S; Celani L; Cardellino CS; Spanu T; Marchese A; Ambretti S; Cauda R; Viscoli C; Viale P;
J Antimicrob Chemother; 2015 Jul; 70(7):2133-43. PubMed ID: 25900159
[TBL] [Abstract][Full Text] [Related]
15. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation.
Bergamasco MD; Barroso Barbosa M; de Oliveira Garcia D; Cipullo R; Moreira JC; Baia C; Barbosa V; Abboud CS
Transpl Infect Dis; 2012 Apr; 14(2):198-205. PubMed ID: 22093103
[TBL] [Abstract][Full Text] [Related]
16. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes.
Souli M; Galani I; Antoniadou A; Papadomichelakis E; Poulakou G; Panagea T; Vourli S; Zerva L; Armaganidis A; Kanellakopoulou K; Giamarellou H
Clin Infect Dis; 2010 Feb; 50(3):364-73. PubMed ID: 20041768
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
19. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
20. Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China.
Zheng SH; Cao SJ; Xu H; Feng D; Wan LP; Wang GJ; Xiao XG
Infect Dis (Lond); 2018 Jun; 50(6):443-451. PubMed ID: 29303020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
